Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INABNASDAQ:PRPHNASDAQ:RWODNASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINABIN8bio$0.17-1.7%$0.20$0.13▼$1.74$13.73M0.241.85 million shs421,200 shsPRPHProPhase Labs$0.35+2.5%$0.37$0.22▼$5.62$14.57M-0.562.65 million shs678,962 shsRWODRedwoods Acquisition$0.73$0.93$2.22▼$13.10$3.75MN/A108,185 shs22,784 shsUPXIUpexi$10.94-14.1%$4.05$1.90▼$22.57$14.45M0.35814,060 shs371,652 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINABIN8bio-3.37%-1.43%-12.29%-35.77%-82.63%PRPHProPhase Labs-3.05%-2.97%-22.82%-24.20%-92.63%RWODRedwoods Acquisition0.00%0.00%0.00%0.00%-89.63%UPXIUpexi-1.47%+41.44%+468.30%+235.88%+27.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINABIN8bio3.6014 of 5 stars3.55.00.00.02.62.51.3PRPHProPhase Labs1.0311 of 5 stars0.02.00.00.02.71.71.3RWODRedwoods AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AUPXIUpexi0.9616 of 5 stars0.02.00.00.03.33.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINABIN8bio 3.00Buy$6.003,450.30% UpsidePRPHProPhase Labs 0.00N/AN/AN/ARWODRedwoods Acquisition 0.00N/AN/AN/AUPXIUpexi 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RWOD, INAB, PRPH, and UPXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/14/2025INABIN8bioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $6.002/12/2025INABIN8bioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINABIN8bioN/AN/AN/AN/A$0.58 per shareN/APRPHProPhase Labs$6.77M2.15N/AN/A$2.74 per share0.13RWODRedwoods AcquisitionN/AN/AN/AN/AN/AN/AUPXIUpexi$18.63M0.78N/AN/A$2.85 per share3.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINABIN8bio-$30.01M-$0.58N/AN/AN/AN/A-197.15%-130.48%5/8/2025 (Estimated)PRPHProPhase Labs-$16.78M-$1.26N/AN/AN/A-217.64%-62.92%-30.22%5/8/2025 (Estimated)RWODRedwoods AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AUPXIUpexi-$23.66MN/A0.00∞N/AN/AN/AN/A5/12/2025 (Estimated)Latest RWOD, INAB, PRPH, and UPXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025INABIN8bio-$0.06N/AN/AN/AN/AN/A5/8/2025Q1 2025PRPHProPhase Labs-$0.18N/AN/AN/A$2.45 millionN/A3/13/2025Q4 2024INABIN8bio-$0.07-$0.04+$0.03-$0.04N/AN/A2/14/2025Q2 2025UPXIUpexiN/A-$1.24N/A-$1.24N/A$4.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINABIN8bioN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ARWODRedwoods AcquisitionN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINABIN8bio0.051.841.84PRPHProPhase Labs0.481.471.33RWODRedwoods AcquisitionN/AN/AN/AUPXIUpexi0.350.580.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINABIN8bio92.05%PRPHProPhase Labs9.45%RWODRedwoods Acquisition20.07%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipINABIN8bio15.50%PRPHProPhase Labs20.70%RWODRedwoods Acquisition2.00%UPXIUpexi34.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINABIN8bio2081.26 million61.25 millionNot OptionablePRPHProPhase Labs13041.88 million18.93 millionOptionableRWODRedwoods AcquisitionN/A5.17 million5.06 millionNot OptionableUPXIUpexi1301.32 million863,000OptionableRWOD, INAB, PRPH, and UPXI HeadlinesRecent News About These CompaniesThis is Why Companies are Diversifying with Cryptocurrencies, Like BitcoinApril 30 at 3:48 PM | baystreet.caCORRECTION FROM SOURCE: Upexi Purchases 45,733 Solana Tokens as it Begins Deploying $100 Million Treasury in Solana StrategyApril 29 at 3:52 PM | finanznachrichten.deUpexi Purchases 45,733 Solana Tokens as it Begins Deploying $100 Million Treasury in Solana StrategyApril 29 at 10:51 AM | finance.yahoo.comInsider Buying: Upexi, Inc. (NASDAQ:UPXI) CFO Purchases 43,860 Shares of StockApril 26, 2025 | insidertrades.comSOL Strategies Channels MicroStrategy With $500M Solana Play—Is Solaxy The Real Winner?April 25, 2025 | insidebitcoins.comUpexi Announces Closing of $100 Million Private PlacementApril 24, 2025 | accessnewswire.comUpexi Stock Surges 630% Following $100M Solana Treasury AnnouncementApril 22, 2025 | blockonomi.comSolana Soars 8% On Institutional Bets As Layer-2 Solaxy Emerges As Future SOL BackboneApril 22, 2025 | insidebitcoins.comWhy Upexi, Inc. (UPXI) Soared on MondayApril 22, 2025 | insidermonkey.comUpexi turns to Solana for Treasury strategy in $100 million deal with GSRApril 22, 2025 | fxstreet.comGSR Anchors $100M Investment in Upexi to Purchase SOL, Stock Rockets 700%April 21, 2025 | finance.yahoo.comUpexi Says It Is Raising $100 Million to Buy Solana Crypto TokenApril 21, 2025 | bloomberg.comUpexi prices 43.86M shares at $2.28 in private placementApril 21, 2025 | markets.businessinsider.comCrypto Stock Upexi, Inc. (NASDAQ:UPXI) Makes NASDAQ Top Percentage GainerApril 21, 2025 | investorideas.comNasdaq-listed Upexi shares up 630% after $100M raise, SOL treasuryApril 21, 2025 | msn.comUpexi Stock Soars Over 600% On $100M Solana Treasury BetApril 21, 2025 | msn.comGSR Leads $100M Private Placement into Nasdaq-listed Upexi, Inc. to Back Solana-Based Treasury StrategyApril 21, 2025 | insidermonkey.comUpexi Announces Pricing of $100 Million Private Placement Priced Above Last Market Closing Price under Nasdaq RulesApril 21, 2025 | accessnewswire.comUpexi subsidiary to acquire 2MW operating facilityMarch 4, 2025 | markets.businessinsider.comUpexi Signs LOI to Purchase Operating Bitcoin Mining FacilityMarch 3, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 High-Yield Dividend Stocks Trading at a DiscountBy Nathan Reiff | April 14, 2025View 3 High-Yield Dividend Stocks Trading at a DiscountRWOD, INAB, PRPH, and UPXI Company DescriptionsIN8bio NASDAQ:INAB$0.17 0.00 (-1.74%) As of 04:00 PM EasternIN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.ProPhase Labs NASDAQ:PRPH$0.35 +0.01 (+2.47%) As of 04:00 PM EasternProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Redwoods Acquisition NASDAQ:RWODRedwoods Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. In intends to focus on businesses in the carbon neutral and energy storage industries. The company was incorporated in 2021 and is based in New York, New York.Upexi NASDAQ:UPXI$10.94 -1.79 (-14.06%) As of 04:00 PM EasternUpexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
